Nerlynx Delays Invasive Disease in Breast Cancer Patients Treated with Herceptin, ExteNET Trial Shows

Nerlynx Delays Invasive Disease in Breast Cancer Patients Treated with Herceptin, ExteNET Trial Shows
Researchers found an increase in invasive disease-free survival (iDFS) in patients with early-stage breast cancer treated with Puma Biotechnology’s Nerlynx (neratinib) after initial treatment with Herceptin (trastuzumab). Quality of life was similar in patients on extended Nerlynx therapy compared with women receiving a placebo, in spite of a drop at the start of treatment. Some of the findings of the Phase 3 ExteNET trial (NCT00878709) were presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain. The presentation, "Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial," was announced in a press release. The U.S. Food and Drug Administration approved the use of Nerlynx to treat women with early stage, HER2-positive breast cancer who have previously been treated with Herceptin. HER2-positive breast cancer tests positive for a protein
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.